DBVT logo DBV Technologies : DBVT

DBVT

Stock Data

$14.55

Change up

$0.31 (2.18%)

Asset Type

Common Stock

Exchange

NASDAQ

Currency

USD

Country

USA

Sector

HEALTHCARE

Industry

BIOTECHNOLOGY

DBV Technologies SA (DBVT) is a pioneering biopharmaceutical company headquartered in Montrouge, France, focused on revolutionizing food allergy treatment through its proprietary Viaskin™ technology platform. As a clinical-stage organization, DBV is dedicated to developing non-invasive epicutaneous immunotherapies aimed at promoting allergen desensitization, with a primary focus on peanut allergies. The company is currently advancing a robust pipeline through a series of clinical trials, positioning itself as a leader in addressing significant unmet medical needs in allergy management while striving to improve patient quality of life.